BC Platforms: Mukhtar Ahmed
BC Platforms has appointed Mukhtar Ahmed as CEO. Ahmed previously served on the board of the UK National Health Service. He also formerly served as president of the science group at Clarivate, president of eHealth at Bioclinica, and global VP for life sciences at Oracle. Additionally, he has held senior leadership positions at Medidata, Parexel, and Kendle.
Arima Genomics: David Duvall, Alex Hastie, William Ricketts
Arima Genomics has appointed David Duvall as senior VP, commercial; Alex Hastie as VP, medical affairs; and William Ricketts as associate VP, clinical evidence generation.
Duvall was most recently VP of sales, South area, for Tempus AI, and was previously head of sales, oncology diagnostic solutions, for Biotheranostics, a Hologic company. He holds a B.S. in management from Radford University.
Hastie most recently served as VP of clinical and scientific affairs at Bionano Genomics. He holds a Ph.D. in molecular biochemistry and biophysics from the University at Buffalo and completed postdoctoral research at the Max Planck Institute for Biochemistry in Munich, Germany.
Ricketts most recently was VP of precision medicine at Ampel BioSolutions. He has also held clinical development and clinical affairs roles at Karius, DxTerity, Ovagene Oncology, and Oncotech. He holds a Ph.D. in biomedical sciences from the University of California, San Diego.
Syncell: Nikhil Rao
Nikhil Rao has been promoted to chief commercial officer of Syncell. He joined the protein purification and spatial proteomics company last year and most recently served as senior VP of commercial. Previously, he held leadership positions at 10x Genomics and at Becton Dickinson. Rao holds a Ph.D. in bioengineering from the University of California, San Diego, and a B.S. in chemical and biomolecular engineering from Johns Hopkins University.
Sapio Sciences: Mike Hampton, Rob Brown
Mike Hampton has been appointed as chief commercial officer of lab informatics firm Sapio Sciences. He has more than two decades of experience from positions at IDBS, a Danaher company, and AI startups. In addition, Rob Brown has been promoted from VP of product and pre-sales to global VP and head of Sapio Sciences' new science office.
Bruker: Laura Francis
Laura Francis has been appointed to the board of directors of Bruker as an independent director. She is also expected to join the company's audit committee as a financial expert after Bruker's annual shareholder meeting at the end of May. Francis is the CEO and a member of the board of SI-BONE, a medical device company. Prior to that, she held executive and leadership roles at various companies including Bruker, Auxogyn, and Promega. She holds a BBA in accounting and finance from the University of Wisconsin and an MBA from Stanford University.
Nuclera: William Kullback
Nuclera has appointed William Kullback to its board of directors as a nonexecutive director. He is the CFO of Telesis Bio and previously served as CFO of BioLegend, now part of Revvity. Kullback holds MBA and bachelor's degrees from the State University of New York at Buffalo.
Singular Genomics Systems: Josh Stahl, Drew Spaventa, Jason Myers
Josh Stahl has been appointed as CEO of Singular Genomics Systems following the firm's acquisition by Deerfield Management. He succeeds former CEO and Cofounder Drew Spaventa, who will continue to serve on the board of directors and become a special adviser to the CEO. Stahl and Jason Myers will join Singular's board of directors.
Immunovia: Karin Almqvist Liwendahl
Karin Almqvist Liwendahl is stepping down as CFO of Immunovia at the end of the first quarter as the company is shifting its focus to the US market. CEO Jeff Borcherding and the firm's finance team members will take over her responsibilities while Immunovia is searching for a successor.
For additional recent items on executive appointments, promotions, and departures in the omics and molecular diagnostics space, please see the People in the News page on our website.